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Introduction {#sec006}
============

Azithromycin is a broad spectrum antibiotic used to treat infectious diseases such as pneumonia, middle ear infections, chlamydia, gonorrhoea and malaria. It has also been used in mass drug administration (MDA) campaigns to control trachoma \[[@pone.0206348.ref001]\]. Such campaigns have reported beneficial effects beyond the target disease. In Ethiopia, MDA with azithromycin for trachoma control reduced all-cause mortality in 1--9 years old children by 49% \[[@pone.0206348.ref002]\] and in The Gambia MDA reduced asymptomatic pneumococcal carriage \[[@pone.0206348.ref003]\]. While the mechanism underlying the mortality reduction reported in Ethiopia was not clear, *Porco et al* suggested that it may have been due to an improvement in nutritional status among children who received azithromycin \[[@pone.0206348.ref002]\]. A subsequent systematic review of the association between antibiotic use and growth found that antibiotic use promotes linear growth and weight gain in children in low and middle-income countries \[[@pone.0206348.ref004]\], where the prevalence of malnutrition in children is high. The hypothesis is also supported by data from randomized clinical trials using azithromycin and anti-malarial drugs during pregnancy, which have shown that this combination increases birth weight \[[@pone.0206348.ref005]--[@pone.0206348.ref007]\] and reduced the incidence of stunting in childhood \[[@pone.0206348.ref008]\].

We recently conducted a trial in Western Gambia in which women in labour were randomized to receive oral azithromycin or placebo \[[@pone.0206348.ref009]\]. The primary outcome of the trial was neonatal nasopharyngeal carriage of *Staphylococcus aureus*, Group B Streptococcus or *Streptococcus pneumoniae*. Maternal bacterial carriage in the nasopharynx, breast milk and low vaginal tract were also assessed. Prevalence of carriage of study bacteria was lower in the first month after birth in mothers who had received azithromycin and their newborns \[[@pone.0206348.ref010]\]. In addition, fewer episodes of maternal and neonatal illness were reported in the azithromycin arm during the 8 weeks of follow-up \[[@pone.0206348.ref011]\].

We conducted a follow up visit of children at 1 year of age, to compare child growth between those who were exposed to azithromycin (because the mother received azithromycin during labour) and those who were not exposed. Our hypothesis was that by reducing bacterial carriage during early life, azithromycin would reduce malnutrition, a major risk factor for child mortality \[[@pone.0206348.ref012]\].

Methods {#sec007}
=======

Study site and population {#sec008}
-------------------------

The study was based at the Jammeh Foundation for Peace (JFP), a government-run health centre located in Western Gambia that manages 4,500 deliveries per year \[[@pone.0206348.ref010]\]. The population covers the main ethnic groups in The Gambia and illiteracy is high. The climate of the area is typical of the sub-Sahel region.

Main trial {#sec009}
----------

The study protocol has been described elsewhere \[[@pone.0206348.ref009]\]. Briefly, this was a phase-III, double-blind, placebo-controlled trial in which 829 pregnant women attending the labour ward in JFP were randomized to receive a single oral dose of 2g of either oral azithromycin or placebo (ratio 1:1). The primary endpoint of the trial was prevalence of *S*. *aureus*, GBS or *S*. *pneumoniae* carriage in the NPS sample of the newborn at day 6 and secondary endpoints included disease and hospitalization in women and newborns during the 8 weeks of follow up. Secondary analysis included estimating the effect of the intervention on clinical disease during the 8 weeks of follow-up \[[@pone.0206348.ref011]\]. The trial started in April 2013 and lasted 14 months.

The packaging and labeling of the investigational medicinal product (IMP) was conducted byIdifarma. Azithromycin and placebo were provided as tablets packed in blisters. One blister pack of IMP contained 4 tablets of 0.5g (2g) of either azithromycin or placebo. The randomisation list was created by an independent data manager and Idifarma numbered the blisters according to the list \[[@pone.0206348.ref009]\]. The active drug and the placebo looked identical.

Follow-up visit during infancy {#sec010}
------------------------------

Between November 2014 and May 2015, a follow-up visit at home was conducted for children aged 11--13 months whose mothers had been randomized to receive either an oral dose of 2g of azithromycin (exposed) or placebo (non-exposed). These children were visited at home by a trained nurse blind to the treatment allocation and anthropometric measurements were recorded. Children were weighed on a standard calibrated scale (Tanita scale) which measures to a precision of 0.1kg. Height was measured using a standard calibrated length board with a precision of 0.1cm. We used a standard coloured and gradated tape to measure mid-upper-arm circumference (MUAC) and a suitable measuring tape for the head circumference, both with a precision of 0.1cm. During the visits, the nurse also transcribed height and weight measurements from the infant's health card onto the study questionnaire.

Ethical approval {#sec011}
----------------

Both the main trial and the adhoc follow up visit were approved by the Joint MRC/Gambia Government Ethics Committee. Mothers of children participating in the survey signed an additional informed consent.

Statistical analysis {#sec012}
--------------------

Study questionnaires were reviewed before being double entered into *OpenClinica* ([www.openclinica.com](http://www.openclinica.com/)). We used WHO child-growth standards to calculate Z-scores for height-for-age (HAZ), weight-for-age (WAZ), weight-for-height (WHZ), body mass index-for-age, head circumference-for-age, and MUAC for age \[WHO Anthro version 3.2.2, January 2011\]. Children with z-scores \<-2SD and \<-3SD were classified as malnourished and severely-malnourished, respectively \[[@pone.0206348.ref013]\]. For each score, we used risk ratios and Fisher's exact test to compare the proportion with a Z-score\<-2 SD and \<-3SD between the study arms. In addition, we used weight measurements transcribed from the welfare-card and measurements taken at 12 months to estimate growth curves (0--12 months) for children in each trial arm. The curves were estimated by fitting a spline function to the weight data using random effects linear regression. No other covariates were included in the regression. The standardized residuals obtained from fitting these models were compared between arms (residuals were standardized by dividing by the standard deviation of the residuals). Specifically, we compared the proportion of standardized residuals\<-2 SD using logistic regression, with cluster-robust variance estimates. We used a p-value cut-off of 0.05 to define statistical significance. Analyses were done using Stata version 14.1.

Results {#sec013}
=======

Study profile {#sec014}
-------------

In the trial, 829 women were recruited during labour, and 830 children were born alive, of whom 814 survived until the end of the 8-week follow-up period. Out of 814 children alive at 8-weeks, 5 had died and 196 were \>13 months at the time of the survey. Among the 613 study children ≤13 months of age at the time of starting the long-term survey, 465 (76.0% of 613 and 57% of the 814) participated in the follow up visit ([S1 Fig](#pone.0206348.s002){ref-type="supplementary-material"}). Characteristics of study participants and non-participants are shown in [Table 1](#pone.0206348.t001){ref-type="table"}.

10.1371/journal.pone.0206348.t001

###### Characteristics of study participants who participated and not in the long term follow-up visit.

![](pone.0206348.t001){#pone.0206348.t001g}

  -----------------------------------------------------------------------------------------------------------------------------
  *Variables*        Categories     12 months survey included (N = 465)\   12 months survey not included (N = 378)\   p-value
                                    n/N (%)                                n (%)                                      
  ------------------ -------------- -------------------------------------- ------------------------------------------ ---------
  Sex                Female         230 (49.5)                             175 (46.3)                                 0.360

  Male               235 (50.5)     203 (53.7)                                                                        

  Ethnicity          Mandinka       201 (43.5)                             151 (41.8)                                 0.367

  Wollof             49 (10.6)      45 (12.5)                                                                         

  Jola               80 (17.3)      47 (13.0)                                                                         

  Fula               76 (16.5)      68 (18.8)                                                                         

  Other              56 (12.1)      50 (13.9)                                                                         

  Maternal\          \<1 year       231 (49.9)                             193 (53.8)                                 0.271
  schooling                                                                                                           

  ≥ 1 year           232 (50.1)     166 (46.2)                                                                        

  Maternal age       18--19 years   30 (6.5)                               37 (9.8)                                   0.109

  20--29 years       295 (63.4)     244 (64.6)                                                                        

  ≥30 years          140 (30.1)     97 (25.7)                                                                         

  Multiple\          No             453 (97.4)                             362 (95.8)                                 0.183
  pregnancy                                                                                                           

  Yes                12 (2.6)       16 (4.2)                                                                          

  Low birth\         No             432 (93.1)                             354 (93.9)                                 0.642
  weight (\<2.5kg)                                                                                                    

  Yes                32 (6.9)       23 (6.1)                                                                          
  -----------------------------------------------------------------------------------------------------------------------------

Baseline characteristics (age at follow up, gender, ethnic group, season at birth, birth weight and maternal age) of children in the azithromycin (n = 226) and the placebo group (n = 239) were similar, except for the higher number of multiple pregnancies in the placebo group (p = 0.037) ([Table 2](#pone.0206348.t002){ref-type="table"}).

10.1371/journal.pone.0206348.t002

###### Characteristics of study participants at birth.

![](pone.0206348.t002){#pone.0206348.t002g}

  ------------------------------------------------------------------------------------------------------------------------------------
  *Characteristics of study children at birth*                                Azithromycin (N = 226)\   Placebo (N = 239)\   p-value
                                                                              n (%)                     n (%)                
  -------------------------------------------------------------- ------------ ------------------------- -------------------- ---------
  Age at follow up (days)                                        Mean (SD)    372.5 (18.4)              373.6(17.7)          0.486

  Mother\'s age (years)                                          Mean (SD)    26.5(5.3)                 26.6(4.9)            0.684

  Birth weight (kg)                                              Mean (SD)    3.1(0.5)                  3.1(0.5)             0.172

  Sex                                                            Female       118 (52.2)                112 (46.9)           0.266

  Male                                                           108 (47.8)   127 (53.1)                                     

  Ethnicity                                                      Madinka      92 (40.7)                 109 (45.6)           0.490

  Jola                                                           45 (19.9)    35 (14.6)                                      

  Wollof                                                         25 (11.1)    24 (10.0)                                      

  Other                                                          64 (28.3)    71 (29.7)                                      

  Apgar score (1 minute)[^2^](#t002fn002){ref-type="table-fn"}   5--6         5 (2.2)                   2 (0.8)              0.232

  7--8                                                           16 (7.1)     10 (4.2)                                       

  9--10                                                          204 (90.7)   224 (94.9)                                     

  Multiple pregnancy                                             No           224 (99.1)                229 (95.8)           0.037

  Yes                                                            2 (0.9)      10 (4.2)                                       

  Season of birth[^1^](#t002fn001){ref-type="table-fn"}          Dry          178 (78.8)                190 (79.5)           0.909

  Rainy                                                          48 (21.2)    49 (20.5)                                      
  ------------------------------------------------------------------------------------------------------------------------------------

^1^Rainy season June- October; Dry season November---May

^2^ n = 1 missing Apgar score in azithromycin arm and n = 3 missing score in placebo arm

Growth curves {#sec015}
-------------

The growth curves were estimated from n = 1,575 measurements in the placebo group (6.6 per child) and 1,472 measurements (6.5 per child) in the placebo group. The curves were similar for both cohorts of children ([S2 Fig](#pone.0206348.s003){ref-type="supplementary-material"}). The proportion of standardized residuals \<-2SD was also similar in both groups \[1.8% versus 3.1%, adjusted OR = 0.59 95% CI (0.22,1.59)\].

12 months follow-up visit {#sec016}
-------------------------

The proportion with MUAC-for-age\<-2SD was significantly lower in the azithromycin group \[1.3% versus 6.3%, RR = 0.21 95% CI (0.06,0.72)\] ([Table 3](#pone.0206348.t003){ref-type="table"}). For all other anthropometrical measures the proportions were similar in both groups.

10.1371/journal.pone.0206348.t003

###### Anthropometrical measurements for nutritional status by study group at the follow-up visit.

![](pone.0206348.t003){#pone.0206348.t003g}

  ----------------------------------------------------------- ----------------------------- ---------------- ----------------- -------------
  ***Mean (SD)***                                             **Azithromycin (N = 226)**\   **Placebo**\                       
                                                              **Mean (SD)**                 **(N = 239)**\                     
                                                                                            **Mean (SD)**                      

  *Age at follow-up (days)*                                   372.47(18.39)                 373.64(17.70)                      

  Height (cm)                                                 71.7(2.8)                     71.7(3.0)                          

  Weight (kg)                                                 8.8(1.1)                      8.8(1.2)                           

  Head circumference (cm)                                     45.5(1.5)                     45.4(1.6)                          

  MUAC (cm)                                                   14.4(1.1)                     14.3(1.3)                          

  ***Z-score \<-2SD***\                                       **Azithromycin (N = 226)**\   **Placebo**\     **RR(95%CI)**     **p-value**
  ***N (%)***                                                 **n (%)**                     **(N = 239)**\                     
                                                                                            **n (%)**                          

  WAZ[^1^](#t003fn001){ref-type="table-fn"} \<-2SD            16(7.1)                       29(12.1)         0.58(0.33,1.04)   0.065

  HAZ[^2^](#t003fn002){ref-type="table-fn"} \<-2SD            58(25.7)                      76(31.8)         0.81(0.60,1.08)   0.144

  BMI[^3^](#t003fn003){ref-type="table-fn"}-for-age \<-2SD    3(1.3)                        8(3.3)           0.40(0.11,1.48)   0.152

  WHZ[^4^](#t003fn004){ref-type="table-fn"} \<-2SD            5(2.2)                        8(3.3)           0.66(0.22,1.99)   0.458

  MUAC[^5^](#t003fn005){ref-type="table-fn"}-for-age \<-2SD   3(1.3)                        15(6.3)          0.21(0.06,0.72)   0.006

  Head circumference-for-age \<-2SD                           9(4.0)                        9(3.8)           1.06(0.43,2.62)   0.904

  ***Z-score \<-3SD***\                                       **Azithromycin (N = 226)**\   **Placebo**\     **RR(95%CI)**     **p-value**
  ***N (%)***                                                 **n (%)**                     **(N = 239)**\                     
                                                                                            **n (%)**                          

  WAZ[^1^](#t003fn001){ref-type="table-fn"} \<-3SD            3(1.3)                        5(2.1)           0.63(0.15,2.62)   0.526

  HAZ[^2^](#t003fn002){ref-type="table-fn"} \<-3SD            14(6.2)                       18(7.5)          0.82(0.42,1.61)   0.569

  BMI[^3^](#t003fn003){ref-type="table-fn"}-for-age \<-3SD    0(0.0)                        2(0.8)           0.00(NA,NA)       0.168

  WHZ[^4^](#t003fn004){ref-type="table-fn"} \<-3SD            0(0.0)                        2(0.8)           0.00(NA,NA)       0.168

  MUAC[^5^](#t003fn005){ref-type="table-fn"}-for-age \<-3SD   1(0.4)                        2(0.8)           0.53(0.05,5.79)   0.596

  Head circumference-for-age \<-3SD                           1(0.4)                        3(1.3)           0.35(0.04,3.36)   0.343
  ----------------------------------------------------------- ----------------------------- ---------------- ----------------- -------------

^1^WAZ = Weight for age

^2^HAZ = Height for age

^3^BMI = Body mass index

^4^WHZ = Weight for height

^5^MUAC = mid-upper-arm circumference

Proxy signs for nutritional status were similar between groups ([Table 4](#pone.0206348.t004){ref-type="table"}).

10.1371/journal.pone.0206348.t004

###### Proxy signs for nutritional status by study arm.

![](pone.0206348.t004){#pone.0206348.t004g}

  -------------------------------------------------------------------------------------------------------------------------------
  *Signs for Nutritional status*      Azithromycin (N = 224)\   Placebo\     RR (95%CI)                                 p-value
                                      n (%)                     (N = 239)\                                              
                                                                n (%)                                                   
  ----------------------------------- ------------------------- ------------ ------------------------------------------ ---------
  Peeling skin lesions                0(0)                      0 (0)        NA[^1^](#t004fn001){ref-type="table-fn"}   1

  Bilateral pedal oedema              0 (0)                     0 (0)        NA[^1^](#t004fn001){ref-type="table-fn"}   1

  Sparse hair distribution            11(4.9)                   18(7.5)      0.65(0.31,1.35)                            0.257

  Loosely fitting clothing            4(1.8)                    10(4.2)      0.43(0.14,1.34)                            0.176

  Loose or sparse hair distribution   15(6.7)                   24(10.0)     0.67(0.36,1.24)                            0.241
  -------------------------------------------------------------------------------------------------------------------------------

^1^NA = Not applicable

Between the end of the trial (8 weeks) and the follow up home visit, 3 children in the azithromycin and 7 children in the placebo groups had records of hospitalization.

Discussion {#sec017}
==========

Children born to mothers treated with oral azithromycin during labour were less likely to have MUAC standardized z-score \<2SD at around 1 year of age, although the mean MUAC was similar in the two study groups. It is also encouraging that the proportion of undernourished infants (\<2SD for WAZ, HAZ, BMI, WHZ and MUAC) appears to be lower in the azithromycin arm, but these findings are not conclusive because only the difference in MUAC was statistically significant.

Although azithromycin MDA has been shown to be associated with decreased child mortality in Ethiopia \[[@pone.0206348.ref002]\], previous studies have not shown an association with nutritional status \[[@pone.0206348.ref014]\]. However, in the previous studies, azithromycin treatment was part of the Trachoma control strategy and was given as a single dose (either once or annually) mainly to children above 1 year of age. In contrast, in our study, although azithromycin was given at a single dose to study women during labour, it reached the infancy through the breast milk for at least 4 weeks \[[@pone.0206348.ref015]\]. In Malawi, adding azithromycin to the standard intermittent preventive treatment for malaria control during pregnancy showed a reduction of childhood stunting \[[@pone.0206348.ref008]\].

Our intervention might have reduced the incidence of malnutrition by reducing chronic gut inflammation which is common among African children. Alternatively it may have mediated changes in the intestinal microbiome which persisted beyond the trial period. Our results are in line with a systematic review which found that antibiotic use promotes linear growth and weight gain in children in low and middle-income countries \[[@pone.0206348.ref004]\]. Because the azithromycin arm in our study had lower bacterial carriage, our results are also consistent with the results of a previous observational study conducted in India, which found that bacterial nasopharyngeal carriage at the age of two months was associated with increased risk of malnutrition at 6 months \[[@pone.0206348.ref016]\].

Few children in our study had severe malnutrition (Z-scores\<-3) and none had clinical signs of severe malnutrition (peeling skin lesions or bilateral pedal oedema), probably reflecting the good care that these children received during the trial follow-up. This is consistent with the low mortality observed in the study between 2--12 months of age (1/3 of that expected in The Gambia) \[[@pone.0206348.ref017]\], and with the low rate of hospitalization.

The study had a number of limitations. First, it was not powered to detect a difference in malnutrition. Second, approximately 20% of participants from the main trial were older than 13 months at the time of the long term CSS and were not included. The reason for this decision was that growth is strongly age-dependent and, as such, growth statistics are hard to interpret unless they are restricted to a narrow age range. Third, we did not have the resources for additional visits and were therefore unable to take further anthropometric measurements, or collect data on other important variables such as breast feeding practices. Instead we relied on weight measurements recorded on the infant's welfare card, which were sometimes missing, to calculate growth curves.

Conclusions {#sec018}
===========

Our results suggest a possible beneficial effect of giving azithromycin during labour on the risk of infant malnutrition. However, our findings are not conclusive and may be attributable to chance. Larger studies with closer follow-up are warranted to confirm whether the intervention has any effect on nutritional status of the offspring beyond the neonatal period. These studies should record the prevalence of antibiotic resistance as a potential drawback of the intervention \[[@pone.0206348.ref010]\].
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